Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan
Niraj Neupane(Rochester General Hospital), Paolo Tarantino(Harvard University), Sara M. Tolaney(Harvard University), Abhenil Mittal(Princess Margaret Cancer Centre), Abhinav Bhattarai(City of Hope), Sangharsha Thapa(Westchester Medical Center), Kriti Ahuja(Unknown), Ilana Schlam(Harvard University)
Cited by 4
Related Papers
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846
HER2-Low Breast Cancer: Pathological and Clinical Landscape
|Journal of Clinical Oncology|2020|801